DexCom, Inc. $350 Million Convertible Notes Offering

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $350 million aggregate principal amount of its 0.75% senior convertible notes due 2022.

J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as Initial Purchasers.

Headquartered in San Diego, California, DexCom, Inc. is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by health care providers.

The Davis Polk corporate team included partners Alan F. Denenberg (Picture) and Stephen Salmon and associates Max Brunner and Randy Li. The tax team included partner Rachel D. Kleinberg and associates Catherine L. Chu and Liang Zhang. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Stephen Salmon – Davis Polk & Wardwell; Max Brunner – Davis Polk & Wardwell; Randy Li – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Catherine Chu – Davis Polk & Wardwell; Liang Zhang – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Merrill Lynch, Pierce, Fenner & Smith Incorporated; JP Morgan Securities;

Author: Ambrogio Visconti